Oncology Peer Review On-The-Go: Examining Evidence Underlying the NCCN Guidelines for Hematologic Malignancies

Article

On this CancerNetwork® podcast, we examine the scientific evidence behind the National Comprehensive Cancer Network guidelines for hematologic malignancies.

This week, the CancerNetwork® editors review a manuscript published in the July issue of the journal ONCOLOGY® titled, “Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies.” Corresponding author Thejaswi K. Poonacha, MD, MBA, a staff physician and hospitalist in the Department of Internal Medicine at the University of Minnesota Medical Center, joined the show to discuss the conclusions of his colleagues.

The conversation focused on the scientific evidence behind the National Comprehensive Cancer Network guidelines for hematologic malignancies, the different levels of evidence supporting the recommendations, and the main conclusions of the research. Poonacha also shared why he thinks this research is significant for the authors as well as physicians treating patients with hematologic malignancies nationwide.



Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Recent Videos
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Related Content